{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Experimental",
    "query": {
      "condition": "Melanoma, Experimental"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 25,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Experimental&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T15:05:02.538Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01106040",
      "title": "Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Lymphoseek",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Navidea Biopharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 163,
      "start_date": "2010-06",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2013-06-17",
      "last_synced_at": "2026-07-23T15:05:02.538Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01106040"
    },
    {
      "nct_id": "NCT03693378",
      "title": "A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Familial Pancreatic Cancer",
        "FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Immunovia, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1349,
      "start_date": "2016-01-19",
      "completion_date": "2021-11-12",
      "has_results": false,
      "last_update_posted_date": "2022-03-31",
      "last_synced_at": "2026-07-23T15:05:02.538Z",
      "location_count": 13,
      "location_summary": "Stanford, California • New Haven, Connecticut • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03693378"
    },
    {
      "nct_id": "NCT03329846",
      "title": "An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma",
        "Skin Cancer"
      ],
      "interventions": [
        {
          "name": "BMS-986205",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-11-30",
      "completion_date": "2020-07-02",
      "has_results": true,
      "last_update_posted_date": "2021-07-09",
      "last_synced_at": "2026-07-23T15:05:02.538Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Miami Beach, Florida + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03329846"
    },
    {
      "nct_id": "NCT00924001",
      "title": "Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Malignant Melanoma",
        "Melanoma, Experimental"
      ],
      "interventions": [
        {
          "name": "DMF5 Melanoma Reactive TIL",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2007-08",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2012-10-25",
      "last_synced_at": "2026-07-23T15:05:02.538Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00924001"
    },
    {
      "nct_id": "NCT04700072",
      "title": "Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab/Quavonlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 56,
      "start_date": "2021-05-03",
      "completion_date": "2025-10-17",
      "has_results": false,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-07-23T15:05:02.538Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04700072"
    },
    {
      "nct_id": "NCT00068003",
      "title": "Harvesting Cells for Experimental Cancer Treatments",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma",
        "Gastrointestinal Cancer",
        "Metastatic Cancer",
        "Breast Cancer",
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Anti-CD19 CAR PBL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7000,
      "start_date": "2003-09-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-07-23T15:05:02.538Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068003"
    },
    {
      "nct_id": "NCT00044356",
      "title": "Phase II Trial of Allovectin-7® for Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Metastatic Melanoma",
        "Malignant Melanoma",
        "Skin Cancer"
      ],
      "interventions": [
        {
          "name": "Allovectin-7®",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Vical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2001-02",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2011-07-07",
      "last_synced_at": "2026-07-23T15:05:02.538Z",
      "location_count": 16,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Bakersfield, California + 13 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00044356"
    },
    {
      "nct_id": "NCT02595866",
      "title": "Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AIDS-Related Non-Hodgkin Lymphoma",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Hepatocellular Carcinoma",
        "HIV Infection",
        "Kaposi Sarcoma",
        "Locally Advanced Lung Non-Small Cell Carcinoma",
        "Locally Advanced Malignant Solid Neoplasm",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Non-Hodgkin Lymphoma",
        "Recurrent Classic Hodgkin Lymphoma",
        "Recurrent Malignant Neoplasm",
        "Refractory Classic Hodgkin Lymphoma",
        "Refractory Malignant Neoplasm",
        "Stage III Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Antiretroviral Therapy",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2016-04-04",
      "completion_date": "2024-03-25",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-07-23T15:05:02.538Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02595866"
    },
    {
      "nct_id": "NCT03068455",
      "title": "An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1844,
      "start_date": "2017-04-11",
      "completion_date": "2021-02-02",
      "has_results": true,
      "last_update_posted_date": "2021-09-20",
      "last_synced_at": "2026-07-23T15:05:02.538Z",
      "location_count": 33,
      "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 25 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03068455"
    },
    {
      "nct_id": "NCT02763761",
      "title": "An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Melanoma",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Infliximab + Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone + Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-08-16",
      "completion_date": "2017-03-31",
      "has_results": false,
      "last_update_posted_date": "2018-10-09",
      "last_synced_at": "2026-07-23T15:05:02.538Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02763761"
    }
  ]
}